Drug maker Vifor Pharma has offered to rectify its disparaging campaign against the closest rival to its blockbuster iron deficiency medicine Ferinject, EU antitrust regulators said on Friday, a move that would stave off a potential hefty fine and end an antitrust investigation.The post Vifor Pharma offers to rectify anti-competitive behavior against rival appeared first on PharmaLive.
Vifor Pharma is a Switzerland-based pharmaceutical company that develops nephrology and cardio-renal therapies for the treatment of heart failure and kidney diseases.